Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: Results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation

Journal of Clinical Psychiatry

Volumn 67, Issue 1, 2006, Pages 137-147

  Swanson, James M ^a   Greenhill, Laurence L ^b   Lopez, Frank A ^c   Sedillo, Andrew ^d   Earl, Craig Q ^e   Jiang, John G ^e   Biederman, Joseph ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c Children's Developmental Center   (United States)

^d Pedia Research   (United States)

^e CEPHALON INC   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADDREAL; AMPHETAMINE; ATOMOXETINE; METHYLPHENIDATE; MODAFINIL; PLACEBO;

ABDOMINAL PAIN; ADOLESCENT; APPETITE DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; FILM COATING; HEADACHE; HUMAN; INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINITIS; SIDE EFFECT;

EID: 32244431543     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0120     Document Type: Article

References (46)

1. American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 2000;105:1158-1170
2. Greenhill LL. Attention-deficit hyperactivity disorder: the stimulants. Child Adolesc Psychiatr Clin North Am 1995;4:123-169
3. Swanson JM. Role of executive function in ADHD. J Clin Psychiatry 2003;64:35-39
4. Wilens TE, Spencer TJ. The stimulants revisited. Child Adolesc Psychiatr Clin N Am 2000;9:573-603
5. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 2002;63(suppl 12):50-55
6. Garland EJ. Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats. J Psychopharmacol 1998; 12:385-395
7. Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunohistochemistry in the cat. Proc Natl Acad Sci U S A 1996;93:14128-14133
8. Engber TM, Koury EJ, Dennis SA, et al. Differential patterns of c-fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neurosci Lett 1998;241:95-98
9. Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000;20:8620-8628
10. Myrick H, Malcolm R, Taylor B, et al. Modafinil: preclinical, clinical, and post-marketing surveillance: a review of abuse liability issues. Ann Clin Psychiatry 2004;16:101-109
11. Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 2000;14:53-60
12. Rush CR, Kelly TH, Hays LR, et al. Acute behavioral and physiological effects of modafinil in drug abusers. Behav Pharmacol 2002;13:105-115
13. Rugino TA, Copley TC. Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study. J Am Acad Child Adolesc Psychiatry 2001;40:230-235
14. Rugino TA, Samsock TC. Modafinil in children with attention-deficit hyperactivity disorder. Pediatr Neurol 2003;29:136-142
15. Swanson JM, Greenhill LL, Biederman J. Modafinil in children with ADHD: a randomized, placebo-controlled study. In: Syllabus and Scientific Proceedings in Summary Form, 156th Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, Calif: 45
16. Labellarte MJ. Pharmacokinetics and effect of modafinil in children with ADHD. Presented at the 47th annual meeting of the American Academy of Child and Adolescent Psychiatry; October 24-29, 2000; New York, NY
17. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998;43:88-97
18. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000;54:1166-1175
19. Gabrielsson J, Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. Stockholm, Sweden: Swedish Pharmaceutical Press; 1994
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000
21. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976
22. DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. New York, NY: Guilford Press; 1998
23. Wechsler D. Wechsler Intelligence Scale for Children-Third Edition (WISC-III). San Antonio, Tex: Psychological Corporation; 1991
24. Wechsler D. Wechsler Individual Achievement Test-Second Edition-Abbreviated (WIAT-II-A). San Antonio, Tex: Psychological Corporation; 2001
25. National Center for Health Statistics and National Center for Chronic Disease Prevention and Health Promotion. 2000 CDC Growth Charts: United States. Available at: http://www.cdc.gov/growthcharts. Accessibility verified Nov 14, 2005
26. Greenberg LM, Kindschi CL, Corman CM. Test of Variables of Attention: Clinical Guide. Minneapolis, Minn: Attention Tech, Inc; 2000
27. Forbes GB. Clinical utility of the Test of Variables of Attention (TOVA) in the diagnosis of attention-deficit/hyperactivity disorder. J Clin Psychol 1998;54:461-476
28. Conners CK. Conners' Parent Rating Scales-Revised: Short Form (CPRS-R:S). North Tonawanda, NY: Multi-Health Systems, Inc; 1997
29. Gresham FM, Elliot SN. Social Skills Rating Scale. Circle Pines, Minn: American Guidance Service; 1990
30. Landgraf JM, Abetz L, Ware JE. The Child Health Questionnaire (CHQ): A User's Manual. Boston, Mass: HealthAct; 1999
31. Biederman J, Lopez F, Swanson JM, et al, for the Modafinil ADHD Study Group. Modafinil improves ADHD symptoms in children in a randomized, double-blind, placebo-controlled study. Presented at the 156th annual meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, Calif
32. Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. San Diego, Calif: Academic Press; 1985
33. Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 2002; 11:1-190
34. Ogden CL, Kuczmarski RJ, Flegal KM, et al. Centers for Disease Control 2000 Growth Charts for the United States: improvements to the 1977 National Center for Health Statistics Version. Pediatrics 2002;109: 45-60
35. Swanson JM, Boellner SW, Rugino TA, et al. Modafinil film-coated tablets (FCT) in children and adolescents with ADHD. Presented at the 158th annual meeting of the American Psychiatric Association; May 21-26, 2005; Atlanta, Ga
36. Greenhill LL, Wigal SB, Kratochvil CJ, et al. ADHD symptoms are improved with modafinil film-coated tablets (FCT). Presented at the 158th annual meeting of the American Psychiatric Association; May 21-26, 2005; Atlanta, Ga
37. Swanson JM. Compliance with stimulants for attention-deficit/ hyperactivity disorder: issues and approaches for improvement. CNS Drugs 2003;17:117-131
38. Carlson GA, Kelly KL. Stimulant rebound: how common is it and what does it mean? J Child Adolesc Psychopharmacol 2003;13: 137-142
39. Nolan EE, Gadow KD, Sprafkin J. Stimulant medication withdrawal during long-term therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Pediatrics 1999;103:730-737
40. Wernicke JF, Adler L, Spencer T, et al. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol 2004;24:30-35
41. Charach A, Ickowicz A, Schachar R. Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry 2004;43:559-567
42. Efron D, Jarman FC, Barker MJ. Child and parent perceptions of stimulant medication treatment in attention deficit hyperactivity disorder. J Paediatr Child Health 1998;34:288-292
43. Kratochvil C, Heiligenstein J, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002;41:776-784
44. Stowe CD, Gardner SF, Gist CC, et al. 24-Hour ambulatory blood pressure monitoring in male children receiving stimulant therapy. Ann Pharmacother 2002;36:1142-1149
45. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002;159: 1896-1901
46. Greenhill LL, Abikoff H, Chuang S, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. In press